胆汁酸代谢与非酒精性脂肪性肝病

doi:10.16139/j.1007-9610.2019.04.020

摘要/Abstract

中图分类号:

R575.5

陈超波, 蒋兆彦. 胆汁酸代谢与非酒精性脂肪性肝病[J]. 外科理论与实践, 2019, 24(04): 371-374.

[1] Satapathy SK, Sanyal AJ.Epidemiology and natural history of nonalcoholic fatty liver disease[J]. Semin Liver Dis,2015,35(3):221-235.
[2] Angulo P, Lindor KD. Non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol,2002,17 Suppl:S186-S190.
[3] Wu R, Hou F, Wang X, et al.Nonalcoholic fatty liver disease and coronary artery calcification in a northern Chinese population: a cross sectional study[J]. Sci Rep,2017,7(1):9933.
[4] Copple BL, Li T.Pharmacology of bile acid receptors: evolution of bile acids from simple detergents to complex signaling molecules[J]. Pharmacol Res,2016,104:9-21.
[5] Song P, Rockwell CE, Cui JY, et al.Individual bile acids have differential effects on bile acid signaling in mice[J]. Toxicol Appl Pharmacol,2015,283(1):57-64.
[6] Wang C, Yang C, Chang JY, et al.Hepatocyte FRS2alpha is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity[J]. Curr Mol Med,2014,14(6):703-711.
[7] Deutschmann K, Reich M, Klindt C, et al.Bile acid receptors in the biliary tree: TGR5 in physiology and di-sease[J]. Biochim Biophys Acta,2018,1864(4 Pt B):1319-1325.
[8] Arab JP, Karpen SJ, Dawson PA, et al.Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives[J]. Hepatology,2017,65(1):350-362.
[9] Schaap FG, Trauner M, Jansen PL.Bile acid receptors as targets for drug development[J]. Nat Rev Gastroenterol Hepatol,2014,11(1):55-67.
[10] Mazuy C, Helleboid A, Staels B, et al.Nuclear bile acid signaling through the farnesoid X receptor[J]. Cell Mol Life Sci,2015,72(9):1631-1650.
[11] Carr RM, Reid AE.FXR agonists as therapeutic agents for non-alcoholic fatty liver disease[J]. Curr Atheroscler Rep,2015,17(4):500.
[12] Fuchs CD, Traussnigg SA, Trauner M.Nuclear receptor modulation for the treatment of nonalcoholic fatty liver disease[J]. Semin Liver Dis,2016,36(1):69-86.
[13] Cariou B, Chetiveaux M, Zair Y, et al.Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults[J]. Nutr Metab (Lond),2011,8(1):48.
[14] Jahn D, Rau M, Hermanns HM, et al.Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease[J]. Cytokine Growth Factor Rev,2015, 26(6):625-635.
[15] Pols TW, Noriega LG, Nomura M, et al.The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation[J]. J Hepatol,2011,54(6):1263-1272.
[16] Broeders EP, Nascimento EB, Havekes B, et al.The bile acid chenodeoxycholic acid increases human brown adipose tissue activity[J]. Cell Metab,2015,22(3):418-426.
[17] Perino A, Schoonjans K.TGR5 and immunometabolism: insights from physiology and pharmacology[J]. Trends Pharmacol Sci,2015,36(12):847-857.
[18] Boursier J, Mueller O, Barret M, et al.The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J]. Hepatology,2016,63(3):764-775.
[19] Ridlon JM, Bajaj JS.The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics[J]. Acta Pharm Sin B,2015,5(2):99-105.
[20] Kohli R, Myronovych A, Tan BK, et al.Bile acid signa-ling: Mechanism for bariatric surgery, cure for NASH?[J]. Dig Dis,2015,33(3):440-446.
[21] Fang S, Suh JM, Reilly SM, et al.Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance[J]. Nat Med,2015,21(2):159-165.
[22] Parseus A, Sommer N, Sommer F, et al.Microbiota-induced obesity requires farnesoid X receptor[J]. Gut,2017, 66(3):429-437.
[23] Ali AH, Carey EJ, Lindor KD.Recent advances in the development of farnesoid X receptor agonists[J]. Ann Transl Med,2015,3(1):5.
[24] Liu X, Xue R, Ji L, et al.Activation of farnesoid X receptor(FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction[J]. Biochem Biophys Res Commun,2014,450(1):117-123.
[25] Fickert P, Fuchsbichler A, Moustafa T, et al.Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts[J]. Am J Pathol,2009,175(6):2392-2405.
[26] Mudaliar S, Henry RR, Sanyal AJ, et al.Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease[J]. Gastroenterology,2013,145(3):574-582,e571.
[27] Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial[J]. Lancet,2015,385(9972):956-965.
[28] Jiang C, Xie C, Lv Y, et al.Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction[J]. Nat Commun,2015,6:10166.
[29] Prawitt J, Abdelkarim M, Stroeve JH, et al.Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity[J]. Diabetes,2011,60(7):1861-1871.
[30] McMahan RH, Wang XX, Cheng LL, et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease[J]. J Biol Chem,2013,288(17):11761-11770.
[31] Armstrong MJ, Gaunt P, Aithal GP, et al.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study[J]. Lancet,2016,387(10019):679-690.
[32] Ferrebee CB, Dawson PA.Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids[J]. Acta Pharm Sin B,2015,5(2):129-134.
[33] Gawrieh S, Chalasani N.Pharmacotherapy for nonalcoholic fatty liver disease[J]. Semin Liver Dis,2015,35(3):338-348.
[34] Leuschner UF, Lindenthal B, Herrmann G, et al.High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial[J]. Hepatology,2010,52(2):472-479.
[35] Beraza N, Ofner-Ziegenfuss L, Ehedego H, et al.Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis[J]. Gut,2011,60(3):387-396.
[36] Safadi R, Konikoff FM, Mahamid M, et al.The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol,2014,12(12):2085-2091.

胆汁酸代谢与非酒精性脂肪性肝病

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈聪燕, 王俊青, 陈拥军. 肠道菌群与肝癌的发病机制[J]. 外科理论与实践, 2022, 27(3): 256-260.
[2]	潘琼, 李明巧, 谭雅, 余思睿, 柴进. 胆酸转运蛋白调控胆汁酸代谢的分子机制[J]. 内科理论与实践, 2022, 17(01): 4-10.
[3]	许飞, 尹明月, 王伟, 董治亚, 陆文丽, 余熠, 王歆琼, 王俊祺, 肖园. 性早熟女童肠道菌群和抗生素耐药性的宏基因组分析[J]. 诊断学理论与实践, 2022, 21(01): 52-61.
[4]	高铭, 李娜, 刘煜. 脑-肠轴与2型糖尿病相关性的研究进展[J]. 内科理论与实践, 2021, 16(06): 418-421.
[5]	李林, 安静静, 王俊祺, 王歆琼, 董治亚. 16S rRNA第二代测序技术分析特发性身材矮小儿童肠道菌群构成的特征及相关发病机制研究[J]. 诊断学理论与实践, 2021, 20(02): 149-154.
[6]	李少博, 杨迪, 韩峻峰. 身体成分变化与非酒精性脂肪性肝病的相关研究进展[J]. 诊断学理论与实践, 2021, 20(01): 104-108.
[7]	李惠, 冯洁, 韩立中. 高通量测序技术分析无特定病原体级实验小鼠肠道的菌群组成[J]. 诊断学理论与实践, 2020, 19(1): 55-62.
[8]	安静静, 王俊祺, 肖园, 陆文丽, 李林, 王伟, 董治亚. 16S rRNA高通量测序分析肠道菌群对小于胎龄大鼠生长追赶的影响及其可能的机制[J]. 诊断学理论与实践, 2020, 19(04): 375-380.
[9]	张雪莹, 秦环龙. 肠道菌群作为结肠直肠癌生物标志物及其干预的临床意义[J]. 外科理论与实践, 2020, 25(02): 155-158.
[10]	陈瑶瑶, 顾爱华. 氧化三甲胺与心血管疾病关系的研究进展[J]. 诊断学理论与实践, 2019, 18(2): 237-240.
[11]	陆启帆, 蒋兆彦, 王启晗, 赵刚, 胡海. 牛磺熊去氧胆酸预防高脂饮食小鼠胆囊结石的研究[J]. 外科理论与实践, 2019, 24(06): 522-529.
[12]	朱雯, 邓婵娟, 代华杰, 禤立平, 李勉, 陈宇红, 张寅飞, 王卫庆, 毕宇芳, 徐敏, 郑昇,. 胰岛素抵抗指数与非酒精性脂肪性肝病肝纤维化进展程度的相关性研究[J]. 内科理论与实践, 2019, 14(06): 342-348.
[13]	石云, 方云芬, 代华杰, 陈晓鸥, 谭利民, 汤明明, 唐志军, 朱雯, 邓婵娟, 禤立平, 王天歌, 徐敏, 毕宇芳, 王卫庆, 张寅飞,. 尿液pH值和非酒精性脂肪性肝病的相关性研究[J]. 内科理论与实践, 2019, 14(06): 337-341.
[14]	汪婷婷, 郑乃盛, 袁向亮, 沈立松. 基于16S rRNA高通量测序技术分析小鼠实验性结肠炎肠道菌群结构特征[J]. 诊断学理论与实践, 2019, 18(03): 263-270.
[15]	蒋兆彦, 胡海, 韩天权, 张圣道. 肠道菌群改变与胆固醇结石病[J]. 外科理论与实践, 2019, 24(02): 93-95.